A pilot study investigating antitumorigenic potential of topical itraconazole in the treatment of basal cell carcinoma
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being done to study the molecular effects of topically applied itraconazole ointment on the growth of basal cell carcinomas.
People over 18 years of age who have been diagnosed with basal cell carcinoma by their doctor and who are awaiting surgery may join the study.
Basal cell carcinoma is the most common type of skin cancer in Caucasians worldwide. Although rarely metastatic, it can be locally destructive causing disfigurement and pain. Current therapies include surgical removal, local destruction, radiotherapy and others. Advances in understanding the molecular basis behind BCCs indicate that mutations in the hedgehog signaling pathway can lead to the development of many sporadically occurring BCCs. An oral drug that targets the hedgehog signaling pathway has been shown to be effective in treating patients with metastatic and inoperable BCCs. There is evidence that itraconazole, a commonly prescribed antifungal medication may also affect this pathway. It is not known whether itraconazole ointment applied topically can affect the growth of BCCs.
07/29/2016 05:03 AM